GlassScriptPhysician profile
Haley Quillen
NPI 1902151616
$2,759.19
in general payments reported to CMS, 2019-2025
17 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $688 · 2023: $571 · 2024: $217 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.11 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $768.08 | 2021-2023 | Xeomin |
| Abbvie INC. | $661.30 | 2022-2025 | |
| Novo Nordisk INC | $623.16 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $261.75 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $79.61 | 2021-2022 | |
| Astellas Pharma US INC | $64.95 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.84 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $40.41 | 2022-2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $39.50 | 2023 | Horizant |
| Amgen INC. | $30.08 | 2022-2024 | Repatha, Otezla |
| Pfizer INC. | $29.00 | 2023-2024 | |
| Organon LLC | $22.47 | 2023 | Nexplanon |
| Intra-Sana Laboratories | $19.41 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Astrazeneca Pharmaceuticals LP | $18.50 | 2022 | |
| Currax Pharmaceuticals LLC | $17.64 | 2023 | Onzetra Xsail, Contrave |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.38 | 2021 | |
| Arcutis Biotherapeutics, INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Quillen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.